ramucirumab,pembrolizumab
merck,eli lilly
['ramucirumab', 'nsclc', 'lung', 'lcsm,(-blcsm)', 's1800a', 'pembro', 'sclc', 'lung-map']
#pembrolizumab plus #ramucirumab to treat non small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the lung-map nonmatched phase 2 substudy s1800a. #asco22 #nsclc #lcsm 
Oncology news and insights from leading researchers and cancer centers.